Full-Time
Account Manager
Roche Sequencing Solutions, d/f/m
Posted on 12/13/2025
Roche
1-10 employees
Global pharmaceuticals and diagnostics company
No salary listed
Pont-de-Claix, France
In Person
 Sales & Account Management (1) |
|---|
- Bachelor’s degree in Life Science, Business, or a related field.
- Proven sales experience in selling capital equipment within the diagnostics/life sciences industry.
- Deep understanding of Next Generation Sequencing and related genomic techniques.
- Demonstrated excellence in negotiation, strategic planning, and organizational abilities.
- Ability to identify technical needs and provide business solutions through consultative selling.
- Strong entrepreneurial spirit with business acumen and drive to navigate complex sales processes.
- Excellent communication skills and ability to deliver impactful group presentations and communicate effectively with diverse stakeholders.
- Willingness to undertake national and international travel.
- Identify and cultivate leads: Discover sales opportunities, cultivate new business relationships, and engage key decision-makers in the sequencing community.
- Execute growth plans: Develop and monitor regional commercial growth plans, focusing on key success metrics to achieve revenue and strategic goals.
- Optimize sales opportunities: Manage sales opportunities effectively through Salesforce/CRM.
- Present and consult: Conduct product presentations and consultative discussions to showcase the value of our sequencing solutions.
- Drive technical sales: Provide technical expertise throughout the sales process, including application consultations and data analysis support.
- Enhance brand visibility: Represent Roche at conferences, trade shows, and networking events to establish thought leadership and engage potential customers.
- Collaborate across teams: Work closely with marketing, product management, service, and support teams to align sales efforts with company objectives and customer needs.
- Regional execution: Partner with subregional teams across Europe to develop and implement strategic plans for successful market penetration.
- Five or more years of experience in a clinical research or academic laboratory environment.
- Experience selling Sequencers for next generation sequencing applications.
- Proficiency in next generation sequencing data analysis.
- Fluent in French and English.
Roche is a global leader in pharmaceuticals and diagnostics. It develops medicines and diagnostic tools that help detect, monitor, and treat diseases, using research and biotechnology to drive new therapies and tests. Roche combines drug development with in-house diagnostic products to support personalized medicine, where treatments are tailored to individual patients based on test results. Its approach differs from many peers by integrating drug discovery with diagnostic capabilities and by expanding its research through strategic acquisitions (like Genentech) to strengthen its biotechnology and R&D capabilities. The company’s goal is to improve patient outcomes and healthcare worldwide by delivering reliable medicines, accurate diagnostic tests, and data-driven care.
Company Size
1-10
Company Stage
IPO
Headquarters
Basel, Switzerland
Founded
1896
Simplify's Take
What believers are saying
- PathAI acquisition for $750M in 2026 scales AI-driven digital pathology globally.
- C4 Therapeutics DAC partnership yields up to $1B in next-gen cancer therapies.
- CT-388 weight-loss drug targets double-digit share against Novo Nordisk, Eli Lilly.
What critics are saying
- Swiss franc appreciation erodes 70% international revenue immediately.
- Avastin, Herceptin patents expire 2028, Amgen biosimilars capture 50% share.
- Tempus-Epic AI pathology platform steals 30% deals from PathAI by Q3 2026.
What makes Roche unique
- Pioneered mass production of synthetic vitamin C in 1934 as Redoxon.
- Acquired Genentech majority stake in 1990, entering biotechnology leadership.
- Secured PCR technology rights from Cetus in 1991 for diagnostics dominance.
Help us improve and share your feedback! Did you find this helpful?
Benefits
Performance Bonus
Company News
SAGA, providing cancer companion diagnostic testing of tissue and non-invasive monitoring of circulating tumor dna (ctdna). Here you'll find information about their funding, investors and team.
Roche has received CE mark approval for its Elecsys Neurofilament Light Chain blood test to detect neuroinflammation in adults with relapsing remitting multiple sclerosis. The test measures NfL, a protein released during nerve cell injury, providing insight into neuroaxonal damage associated with the disease. Multiple sclerosis affects over 2.9 million people worldwide. Whilst early and regular monitoring is critical, patients often struggle to access routine MRI scans. The minimally invasive blood test offers a more accessible alternative, complementing clinical assessments and potentially enabling earlier intervention. The test runs on Roche's widely available cobas instruments, delivering standardised results and requiring only a simple blood sample. This reduces the need for patients to travel to specialist centres, making frequent monitoring more practical where traditional testing faces geographic, financial or logistical barriers.
Roche has partnered with C4 Therapeutics to develop degrader-antibody conjugates (DACs), marking a $20 million upfront payment with potential milestone payments exceeding $1 billion. The collaboration targets cancer therapeutics using C4's Torpedo platform. DACs represent a next-generation approach to antibody-drug conjugates (ADCs). Whilst ADCs attach cytotoxic drugs to antibodies, DACs use targeted protein degradation payloads to selectively eliminate specific proteins within cancer cells, potentially reducing toxicity and drug resistance whilst accessing previously difficult targets. Amongst Korean listed companies, Orum Therapeutics leads DAC development, having licensed ORM-6151 to Bristol Myers Squibb in 2023. Y-Biologics partnered with Ubix Therapeutics, whilst Oscotec is developing three DAC pipelines through subsidiary Genosco, targeting technology transfers after 2028.
Roche has received FDA 510(k) clearance for its cobas c703 and cobas ISE neo analytical units, designed to enhance laboratory efficiency through increased automation and testing capacity. The units are part of Roche's cobas pro integrated solutions platform. The cobas c703 delivers up to 2,000 tests per hour with 70 reagent positions, doubling clinical chemistry throughput whilst reducing reagent reloads. The cobas ISE neo provides up to 1,800 tests per hour with automated maintenance, reducing hands-on time and plastic waste compared to previous systems. Both units feature monthly operator maintenance to improve uptime and help laboratories address staffing shortages and growing test volumes. Roche has over 4,000 cobas analysers installed across the United States.
Roche has launched the cobas MPX-E assay, a four-in-one donor screening test that simultaneously detects HIV, Hepatitis C, B and E viruses. The test is now available in countries accepting the CE mark. The assay consolidates detection of four major viral targets into a single workflow, improving laboratory efficiency and reducing costs. It features dual-target detection for HIV-1 and enhanced sensitivity for Hepatitis E, which causes an estimated 20 million infections and 70,000 deaths annually worldwide. The test runs on Roche's fully automated cobas x800 systems, which process over 10 million tests monthly across laboratories globally. The ready-to-load reagents enable up to eight hours of walk-away time. The nucleic acid testing blood screening market is valued at approximately 800 million Swiss francs globally, with an expected annual growth rate of 2% through 2029.